Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Neurogene (NGNE) over the last 5 years, with Q1 2025 value amounting to 32398.75%.

  • Neurogene's EBIT Margin rose 292793100.0% to 32398.75% in Q1 2025 from the same period last year, while for Sep 2025 it was 121637.5%, marking a year-over-year increase of 1451130400.0%. This contributed to the annual value of 8930.27% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q1 2025, Neurogene's EBIT Margin is 32398.75%, which was up 292793100.0% from 2176.65% recorded in Q2 2024.
  • Neurogene's EBIT Margin's 5-year high stood at 434500.0% during Q1 2023, with a 5-year trough of 2176.65% in Q2 2024.
  • Its 3-year average for EBIT Margin is 116960.38%, with a median of 17759.09% in 2025.
  • As far as peak fluctuations go, Neurogene's EBIT Margin plummeted by 2000000000bps in 2024, and later surged by 292793100bps in 2025.
  • Quarter analysis of 3 years shows Neurogene's EBIT Margin stood at 434500.0% in 2023, then crashed by -101bps to 2176.65% in 2024, then skyrocketed by 1588bps to 32398.75% in 2025.
  • Its EBIT Margin was 32398.75% in Q1 2025, compared to 2176.65% in Q2 2024 and 3119.44% in Q1 2024.